BGLR - Clinical: Beta-Glucuronidase, Fibroblasts

Test Catalog

Test ID: BGLR    
Beta-Glucuronidase, Fibroblasts

Useful For Suggests clinical disorders or settings where the test may be helpful

Detection of mucopolysaccharidosis type VII

Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request

Diagnostic testing. Not recommended for carrier detection.

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

When this test is ordered, a fibroblast culture and cryopreservation for biochemical studies will always be performed at an additional charge. However, for multiple lysosomal enzyme assays on a patient utilizing fibroblast culture, only 1 culture is required regardless of the number of enzyme assays ordered. If viable cells are not obtained within 10 days, client will be notified.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Mucopolysaccharidosis VII (MPS VII, Sly syndrome) is an autosomal recessive lysosomal storage disorder caused by the deficiency of beta-glucuronidase. The mucopolysaccharidoses are a group of disorders caused by the deficiency of any of the enzymes involved in the stepwise degradation of glycosaminoglycans (GAG). Accumulation of GAGs (also called mucopolysaccharides) in lysosomes interferes with normal functioning of cells, tissues, and organs. MPS VII is caused by a reduced or absent activity of the beta-glucuronidase enzyme and gives rise to the physical manifestations of the disease.


Clinical features and severity of symptoms of MPS VII are widely variable ranging from severe lethal hydrops fetalis to more mild forms, which generally present at a later onset with a milder clinical presentation. In general, symptoms may include skeletal anomalies, coarse facies, hepatomegaly, neurological issues, and mental retardation. Treatment options may include bone marrow transplantation. Sly syndrome is 1 of the least common mucopolysaccharidoses with an incidence of 1 in 250,000 live births.


A diagnostic workup in an individual with MPS VII typically demonstrates elevated levels of urinary GAGs and increased amounts of dermatan sulfate, heparan sulfate, and chondroitin 6-sulfate detected on thin-layer chromatography. Reduced or absent activity of beta-glucuronidase in fibroblasts can confirm a diagnosis of MPS VII; however, enzymatic testing is not reliable to detect carriers. Molecular sequence analysis of the GUSB gene allows for detection of the disease-causing mutation in affected patients and subsequent carrier detection in relatives. Currently, no clear genotype-phenotype correlations have been established.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

> or =2.33 nmol/min/mg protein

Interpretation Provides information to assist in interpretation of the test results

Patients with mucopolysaccharidosis type VII (Sly syndrome) are deficient of beta glucuronidase.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Diagnosis of this lysosomal disorder is only available on fibroblasts. Carriers have not been reliably detected by this method.


Interfering factors:

-Lack of viable cells or bacterial contamination

-Failure to transport tissue in an appropriate media

-Excessive transport time,

-Exposure of the specimen to temperature extremes (freezing or >30 degrees C)

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

Neufeld EF, Muenzer J. Neufeld E.F., Muenzer J Neufeld, Elizabeth F., and Joseph Muenzer.The Mucopolysaccharidoses. Edited by D Valle, AL Beaudet, B Vogelstein,et al:New York, NY: McGraw-Hill; 2014. Accessed April 22, 2015. Available at

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Tell Us What You Think